Investors may want to keep an eye on oversold shares of Cassava Sciences (NASDAQ:SAVA). Even with the broader market down 500 points on the day, shares of SAVA are up 5% on a volume spike to 3.48 million shares. The daily average volume is 1.71 million.
This is all as excitement is building over its Alzheimer’s drug, Simufilam. In fact, at the moment, Cassava Sciences has two Phase 3 trials under special protocol assessments with the U.S. Food and Drug Administration (FDA).
More About Cassava Sciences Stock
The post Take Full Advantage of Weakness in Cassava Sciences Stock appeared first on InvestorPlace.